A detailed history of Federated Hermes, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 937,250 shares of SNDX stock, worth $14.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
937,250
Previous 656,250 42.82%
Holding current value
$14.9 Million
Previous $13.5 Million 33.92%
% of portfolio
0.04%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.93 - $24.81 $5.04 Million - $6.97 Million
281,000 Added 42.82%
937,250 $18 Million
Q2 2024

Aug 08, 2024

BUY
$18.82 - $23.79 $2.21 Million - $2.8 Million
117,536 Added 21.82%
656,250 $13.5 Million
Q1 2024

May 14, 2024

BUY
$19.71 - $24.57 $10.6 Million - $13.2 Million
538,714 New
538,714 $12.8 Million
Q2 2020

Aug 13, 2020

SELL
$8.94 - $20.98 $598 - $1,405
-67 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$6.65 - $12.03 $2,081 - $3,765
-313 Reduced 82.37%
67 $1,000
Q4 2019

Feb 14, 2020

SELL
$5.43 - $9.22 $1,346 - $2,286
-248 Reduced 39.49%
380 $3,000
Q3 2019

Nov 14, 2019

SELL
$7.47 - $10.76 $522 - $753
-70 Reduced 10.03%
628 $5,000
Q2 2019

Aug 14, 2019

BUY
$4.9 - $9.31 $612 - $1,163
125 Added 21.82%
698 $6,000
Q4 2018

Feb 13, 2019

BUY
$3.6 - $8.42 $378 - $884
105 Added 22.44%
573 $2,000
Q3 2018

Nov 13, 2018

BUY
$6.33 - $8.08 $1,525 - $1,947
241 Added 106.17%
468 $4,000
Q2 2018

Aug 10, 2018

SELL
$6.93 - $14.63 $1,787 - $3,774
-258 Reduced 53.2%
227 $2,000
Q1 2018

May 09, 2018

BUY
$8.71 - $14.82 $4,224 - $7,187
485 New
485 $7,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.